California: Findings of a new UC San Francisco study suggest that the antibiotic azithromycin was no more effective than a placebo in preventing symptoms of COVID-19 among non-hospitalized patients. Despite widespread antibiotic prescription for the disease, it can increase the chances of hospitalization.
study, which was organized in collaboration with Stanford University, appeared in the Journal of the American Medical Association.
“These findings do not support the routine use of azithromycin for outpatient SARS-CoV-2 infection,” said lead author Katherine E. oldenburghandjob scdhandjob miles per hourMILF with an assistant professor UCSF Proctor Foundation. SARS-CoV-2 is the virus that causes Covid-19.
Azithromycin, a broad-spectrum antibiotic, is widely prescribed as a treatment for COVID-19 in the United States and the rest of the world. “The hypothesis is that it has anti-inflammatory properties that may help prevent progression if treated early in the disease,” Oldenburg said. “We didn’t think that was the case.”
The study involved 263 participants who tested positive for SARS-CoV-2 within seven days before entering the study. No one was hospitalized at the time of enrollment. In a randomized selection process, 171 participants received a single, 1.2-gram oral dose of azithromycin and 92 received an equivalent placebo.
On the 14th day of the study, 50 percent of participants remained symptom-free in both groups. By day 21, five of the participants who received azithromycin were hospitalized with severe symptoms of COVID-19 and none in the placebo group.
The researchers concluded that treatment with a single dose of azithromycin was no more likely to result in symptom-free survival than placebo.
“Most of the trials that have been done with azithromycin so far have focused on hospitalized patients with very severe disease,” Oldenburg said. “Our paper is one of the first placebo-controlled studies to show no role of azithromycin in outpatients.”
study, which was organized in collaboration with Stanford University, appeared in the Journal of the American Medical Association.
“These findings do not support the routine use of azithromycin for outpatient SARS-CoV-2 infection,” said lead author Katherine E. oldenburghandjob scdhandjob miles per hourMILF with an assistant professor UCSF Proctor Foundation. SARS-CoV-2 is the virus that causes Covid-19.
Azithromycin, a broad-spectrum antibiotic, is widely prescribed as a treatment for COVID-19 in the United States and the rest of the world. “The hypothesis is that it has anti-inflammatory properties that may help prevent progression if treated early in the disease,” Oldenburg said. “We didn’t think that was the case.”
The study involved 263 participants who tested positive for SARS-CoV-2 within seven days before entering the study. No one was hospitalized at the time of enrollment. In a randomized selection process, 171 participants received a single, 1.2-gram oral dose of azithromycin and 92 received an equivalent placebo.
On the 14th day of the study, 50 percent of participants remained symptom-free in both groups. By day 21, five of the participants who received azithromycin were hospitalized with severe symptoms of COVID-19 and none in the placebo group.
The researchers concluded that treatment with a single dose of azithromycin was no more likely to result in symptom-free survival than placebo.
“Most of the trials that have been done with azithromycin so far have focused on hospitalized patients with very severe disease,” Oldenburg said. “Our paper is one of the first placebo-controlled studies to show no role of azithromycin in outpatients.”
.